Keeping our shareholders and potential investors up to date and informed about recent news, share price, and other relevant information
The Board of Directors recognises the value and importance of maintaining the highest standards of corporate governance. The Group has decided to adopt the Quoted Companies Alliance Code (the “QCA Code”), which has become a widely recognised benchmark for corporate governance of small and mid-sized companies, particularly AIM companies. The Board has endorsed this decision, and having carefully considered the requirements of the QCA Code, it considers that the Group has complied with the QCA Code during the year and where it hasn’t, has explained the reasons for this. The Board recognises that by strengthening the corporate governance framework, it will also support the overall strategy of BiVictriX. It is fundamental that we embed our values into all areas of BiVictriX operations. The Board is committed to implementing recommended corporate governance improvements to ensure that we attain high standards of corporate governance moving forward.
Please see here for our Statement of Compliance with the QCA Code.
Information last reviewed on 5th August 2021.
The Board
The Board is responsible for formulating, reviewing and approving the Group’s strategy, budgets and corporate actions, and is collectively responsible for the long-term success of the Group. Whilst day-to-day management of the Group is delegated to the senior management team, certain matters are specifically reserved for decision by the Board and documented in a written schedule which is reviewed annually.
Roles & Responsibilities
Please see here for the roles and responsibilities for the Chairman, CEO and each director.
Audit and Risk Committee
The Audit Committee’s role is to assist the Board with the discharge of its responsibilities in relation to internal and external financial reporting, audits and controls, including reviewing the Company’s annual and half-yearly financial statements, reviewing and monitoring the scope of the annual audit and the extent of the non-audit work undertaken by external auditors, advising on the appointment of external auditors and the tendering process and reviewing the effectiveness of the Company’s corporate governance, internal audit and controls, risk management, whistle-blowing and fraud-prevention systems. The ultimate responsibility for reviewing and approving the Company’s annual report and accounts and its half-year reports remains with the Board. The Audit Committee will be chaired by Susan Lowther and its other members will be Drummond Paris and Robert Hawkins. The Board has satisfied itself that has recent and relevant financial experience, and that the committee as a whole has competence relevant to the sector in which theCompany operates. The Audit Committee will normally meet not less than three times in each financial year and at such other times as the chair of the committee requires. It will have unrestricted access to the Company’s auditors.As a matter of course, the Company’s Chairman and Chief Executive Officer will be invited to attend Audit Committee meetings.
Remuneration and Nominations Committee
The Company considers that, at this stage of its development, and given the current size of its board, it is not necessary to establish a formal remuneration or nominations committee. This position will be reviewed on a regular basis by the Board as a whole.
Information last reviewed on 5 August 2021
The following information is disclosed in accordance with Rule 26 of the AIM Rules.
These requirements were last reviewed and updated by the company on 30 May 2022.
Description of the Business
BiVictriX Therapeutics was formed in 2016 and is a rapidly emerging biotechnology company based in the UK. The company focuses on the development of next generation cancer therapies. Read More
Incorporation and Registered Office
BiVictriX Therapeutics Plc is incorporated in England & Wales with registered number 13470690 and registered address of Co Slater Heelis Limited, 86 Deansgate, Manchester, M3 2ER
BiVixtriX's main company of operation is the UK.
Directors
Iain Ross (Non-Executive Chairman)
Tiffany Daniels-Thorn (CEO)
Drummond Paris (Senior Independent Non-Executive Director)
Robert Hawkins (Independent Non-Executive Director)
Susan Lowther (Independent Non-Executive Director)
Dr. Michael Kauffman (Independent Non-Executive Director)
View Directors Biographies
Advisors
Nominated Advisor and Joint Broker
SP Angel Corporate Finance LLP
Prince Frederick House
35-39 Maddox Street
London
W1S 2PP
Joint Broker
Panmure Gordon & Co
One New Change
London
EC4M 9AF
Financial Advisor
Acceleris Capital Limited
CT3, Wigan Investment Centre
Waterside Drive
Wigan
WN3 5BA
Auditor
Crowe
55 Ludgate Hill
London
EC4M 7JW
Financial Communications Advisor
Consilium Strategic Communications
85 Gresham Street
London
EC2V 7NQ
Legal Advisor
Slater Heelis Limited
86 Deansgate
Manchester
M3 2ER
Registrar
Share Registrars Limited
The Courtyard
17 West Street
Farnham
Surrey
GU9 7DR
Documents
Articles of Association - View Here
Admission Document - View Here
Company Announcements - View Here
Company Presentations - View Here
Financial Reports - View Here
Takeover Code
The Company is subject to the UK City Code on Takeovers and Mergers.
Corporate Governance
The Board seeks to follow best practice in corporate governance appropriate with the size and regulatory framework that applies to AIM companies. The Board reviews and applies the principles and provisions of the 2018 Quoted Company Alliance Corporate Governance Code (“Code”) where it is appropriate to do so to support the governance framework.
View more information on corporate governance here
Securities Information
BivictriX is listed solely on the AIM market of the London Stock Exchange. The Company is not listed on any other Exchanges or Trading Platforms.
There are no restrictions on the transfer of securities.
Shares & Significant Shareholders
Total Number of Shares in Issue: 66,115,201 ordinary shares of 1 pence each
Shares Not in Public Hands: 21.3%
Shareholders with 3% or more of the total issued share capital:
Directors Shareholdings